ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CLNN vs ONCY // PIOTROSKI F-SCORE QUALITY

Clene Inc. (NASDAQ) VS. Oncolytics Biotech Inc. (NASDAQ) • 15-METRIC TALLY: CLNN 2 — ONCY 1
▲ PIOTROSKI F-SCORE QUALITY LEADER: CLNN
piotroski-score
3/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CLNN VS. ONCY) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CLNN ONCY SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 78.50% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) -41.50% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality ACTIVE 3/9 2/9 +1.00 CLNN /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 49.4 24.1 +25.31 CLNN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $55.4M $56.1M -$645.8K ONCY /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CLNN REV ONCY REV CLNN GROSS % ONCY GROSS % CLNN FCF ONCY FCF
FY 2025 $200.0K $0 78.5% — -$18.6M -$20.1M
FY 2024 $342.0K $0 79.5% — -$21.3M -$20.1M
FY 2023 $654.0K — — — -$30.2M —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CLNN // BETA —
ONCY // BETA —